GANX - Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
(NewsDirect)
Bethesda, MD,August 29, 2023 ( PlatoData via500NewsWire) -- GainTherapeutics, Inc. ( Nasdaq:GANX ), a pioneering biotechnology company specializing ininnovative allosteric small molecule therapies, has made significantstrides in the fight against Parkinson's disease (PD). TheCompany's lead drug candidate, GT-02287, has demonstratedextraordinary potential in mitigating the effects of Parkinson'sdisease across two distinct preclinical models of the ailment. Thesefindings suggest that GT-02287 has the capacity to alleviateParkinson's disease pathology and enhance motor function.
A notable highlight isthe substantial reduction of plasma Neurofilament Light Chain (NfL)levels, an emerging biomarker for neurodegeneration. This advancementwas demonstrated in a mouse model of GBA1-PD, a discovery that couldhave far-reaching implications for understanding neurodegenerativeconditions.
Thesegroundbreaking findings were presented at the International Congressof Parkinson's Disease and Movement Disorders®, held inCopenhagen, Denmark from August 27 to 31, 2023.
Dr. Joanne Taylor,Senior Vice President of Research at Gain, expressed her excitement,stating, "The data from these preclinical models highlightGT-02287's potential as an oral allosteric regulator of GCase. Therestoration of enzymatic function and reduction in Parkinson'sdisease-related pathologies are promising indicators. Additionally,the significant reduction in plasma NfL levels, a keyneurodegeneration biomarker, holds promise for future clinicaltrials."
Ofsignificant importance is the substantial decrease in plasma NfLlevels observed in the GBA1-PD model, signifying a potentialadvancement in neurodegeneration assessment. The second poster,"GT-02287, a brain-penetrant structurally targeted allostericregulator," scheduled for August 30th, will delve intoGT-02287's impact on a PD animal model, showcasing its potentialto restore protein function and counteract neurotoxic effects.
Matthias Alder, ChiefExecutive Officer of Gain Therapeutics, emphasized the significance ofthese results. He stated, "The data from both posters solidify thepotential of GT-02287 to restore GCase protein function, shieldagainst Parkinson's disease's neurological impact, and reduceneurodegeneration, as indicated by the emerging biomarker NfL. Thesecompelling findings pave the way for Phase 1 clinical trials withGT-02287, marking a pivotal step towards advancing a potentiallygroundbreaking treatment for GBA1 Parkinson's disease." GainTherapeutics' achievements underscore its pivotal role in shapingthe landscape of Parkinson's disease research and treatment.
GAIN Therapeutics:
https://www.gaintherapeutics.com/
https://www.marketscreener.com/quote/stock/GAIN-THERAPEUTICS-INC-120780704/
#CKPT #SKYE #LVTX
Cautionary NoteRegarding Forward-Looking Statements
This press release contains"forward-looking statements" within the meaning of the PrivateSecurities Litigation Reform Act of 1995. All statements in this pressrelease other than statements of historical facts are“forward-looking statements”. In some cases, you can identifythese statements by forward-looking words such as "may,""might," "will," "should," "expect,""plan," "anticipate," "believe,""estimate," "predict," "goal, ""intend," "seek, " "potential" or"continue," the negative of these terms and variations ofthese words or similar expressions that are intended to identifyforward-looking statements, although not all forward-lookingstatements contain these words. Forward-looking statements in thispress release include, but are not limited to, statements regarding:the Company’s observations based upon the reported preclinical data;the Company’s expectations regarding the timing of commencement of aPhase 1 clinical program for GT-02287 for GBA1 Parkinson’s disease;and the potential therapeutic and clinical benefits of GT-02287 forthe treatment of GBA1 Parkinson’s disease. These forward-lookingstatements are based on the Company’s expectations and assumptionsas of the date of this press release. Each of these forward-lookingstatements involves risks and uncertainties that could cause theCompany’s preclinical and future clinical development programs,future results or performance to differ materially from thoseexpressed or implied by the forward-looking statements. Thesestatements are not historical facts but instead represent theCompany's belief regarding future results, many of which, by theirnature, are inherently uncertain and outside the Company'scontrol. Many factors may cause differences between currentexpectations and actual results, including the risk that observationsfrom preclinical studies are not indicative or predictive of resultsin clinical trials; unexpected safety or efficacy data observed duringpreclinical studies or clinical trials, clinical trial site activationor enrollment rates that are lower than expected; the impacts of thepost-COVID-19 environment and other global and macroeconomicconditions on the Company’s business; the Company’s financialposition; changes in expected or existing competition; changes in theregulatory environment; the uncertainties and timing of the regulatoryapproval process; and unexpected litigation or other disputes. Otherfactors that may cause the Company’s actual results to differ fromthose expressed or implied in the forward-looking statements in thispress release are identified in the section titled “Risk Factors,”in the Company’s Annual Report on Form 10-K filed with theSecurities and Exchange Commission on March 23, 2023 and its otherdocuments subsequently filed with or furnished to the Securities andExchange Commission from time to time. All forward-looking statementscontained in this press release speak only as of the date on whichthey were made. The Company undertakes no obligation to update suchstatements to reflect events that occur or circumstances that existafter the date on which they were made, except as required bylaw.
Contact Details
David Zazoff - MDM Worldwide- 264 W 40th St New York NY 10018
Copyright (c) 2023 TheNewswire - All rights reserved.